Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 29, 2026

GBank Financial (GBFH) Q4 2025 Earnings Call Transcript

View original at finance.yahoo.com
GBank Financial (GBFH) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. DATE Wednesday, Jan. 28, 2026, at 5 p.m. ET CALL PARTICIPANTS Chairman and CEO — Edward Nigro Chief Credit Officer — Jeffery Whicker Full Conference Call Transcript Edward Nigro: Well, welcome, everybody…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Expected to maintain NIM at approximately 4.33% with non-interest bearing deposit growth offsetting Fed cuts

    80% confidence
  • Zero fraud penetration in last 60 days after implementing new fraud prevention systems

    80% confidence
  • Goal to replace $400M paid deposits with no-cost deposits via PPA growth

    80% confidence
  • Approximately $2.5M deposits projected per 100 slot machines at 50% market penetration in mature market

    80% confidence
  • Assumes 2 Fed rate cuts in 2026

    80% confidence
  • Credit cards represent approximately 30% of all US payments, approximately $6T annually

    80% confidence
  • Interchange fees drove approximately $7M increase year-over-year in FY2025

    80% confidence
  • Credit card could potentially at least double $400M FY2025 volume, targeting $60-65M monthly by year-end

    80% confidence
  • 65 Parapasu loans originated in 2025 (SBA $5M + additional CRE portion, total approximately $8-10M each)

    80% confidence
  • Q4 2025 record quarterly earnings of $7.4M ($0.52 per diluted share), increase of $3.1M vs. prior quarter

    80% confidence
  • 16 other PPA clients onboarded for various applications including sports apps and state lotteries

    80% confidence
  • Q4 2025 government shutdown prevented approvals and left estimated $2M+ gain on sales on the table

    80% confidence
  • 28 legal sports betting apps nationwide; GBFH customers use 20 of them

    80% confidence
  • Net interest margin of 4.33% in 2025 vs. industry average of approximately 3.7%

    80% confidence
  • Q4 2025 SBA originations of $118M, down from $200M+ in Q3 due to government shutdown

    80% confidence
  • 8-year compound average growth rate of 28.3%

    80% confidence
  • Approximately 7 states prohibit credit card direct loads to sports betting apps

    80% confidence
  • Total SBA exposure of approximately $2.4B on and off balance sheet

    80% confidence
  • January 2026: 12 loans sold for approximately $32M, 8 of 12 at ≥1.25% spread to prime, gap gain ≥4%

    80% confidence
  • Individual lending power increased to 70% of legal limit: $32M to any one borrower

    80% confidence
  • Q3 2025: 592 active hotel loans totaling $1.622B principal on and off balance sheet

    80% confidence
  • Nevada has 150,000 slot machines; US total exceeds 800,000 licensed slot machines

    80% confidence
  • From June 2015 to Q3 2025: originated $2.473B SBA loans (1,002 loans), total defaults of 12 loans, total charge-offs of $2.8M

    80% confidence
  • Credit card transaction volume grew approximately 500% from $73M prior year to $400M in FY 2025

    80% confidence
  • Gain on sale increased from 3.24% to 3.98% in Q4 2025

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com